Sandoz Group Ltd ( (CH:SDZ) ) has shared an announcement.
Sandoz has filed an antitrust lawsuit in the US against Amgen, Inc., alleging that Amgen has unlawfully blocked competition for its biosimilar product, Erelzi®, a cost-effective alternative to the blockbuster drug Enbrel®. Despite FDA approval for Erelzi® in 2016, Sandoz claims Amgen’s actions have prevented its launch, impacting millions of Americans with chronic inflammatory diseases. Sandoz seeks an injunction and damages to facilitate the introduction of Erelzi®, which could provide significant cost savings and expanded access for patients.
More about Sandoz Group Ltd
Sandoz is a global leader in generic and biosimilar medicines, headquartered in Basel, Switzerland. With a history dating back to 1886, the company has pioneered access for patients and offers a portfolio of approximately 1,300 products addressing various diseases. Sandoz employs over 20,000 people and recorded net sales of USD 10.4 billion in 2024.
YTD Price Performance: -5.19%
Average Trading Volume: 3,609
Technical Sentiment Signal: Strong Buy
Current Market Cap: $17.1B
See more insights into SDZ stock on TipRanks’ Stock Analysis page.